Release--Gastrointestinal therapeutics market to decline from $6.8 billion in 2012 to $6.6 billion by 2019
Gastrointestinal therapeutics market to decline from $6.8 billion in 2012 to $6.6 billion by 2019
FOR IMMEDIATE RELEASE
Gastrointestinal therapeutics market to decline from $6.8 billion in 2012 to $6.6 billion by 2019
Humira and Remicade’s patent expiries will hurt the overall market value, says analyst
Gastrointestinal Therapeutics Industry: Promising Drugs in Late-Stage Development Could Stabilize Declining Global Market, says GBI Research
NEW YORK (GBI Research), 15 January 2014
The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis (UC), and Crohn’s disease (CD) in the eight major markets (8MM) — the US, UK, France, Germany, Italy, Spain, Canada and Japan — is expected to decrease in value from $6.8 billion in 2012 to $6.6 billion by 2019, at a negative Compound Annual Growth Rate (CAGR) of 0.3%, forecasts business intelligence provider GBI Research.
According to the firm’s latest report*, the GI market will register different CAGRs across the 8MM during the forecast period. The US and Japan will witness positive CAGRs of 0.2% and 4%, respectively, while the European markets will decline at a negative CAGR of 2.5%. This unfavourable growth is due to the upcoming patent expiry of various major drugs.
Arti Singh, Analyst for GBI Research, says: “As Humira and Remicade account for a substantial share of the GI therapeutics industry, their patent expiries will harm the overall market value. The entry of generics and biosimilars will also have a strong impact on sales.”
However, promising pipeline drugs in the late stages of development could stabilize the current market.
Singh continues: “Three molecules in the pre-registration stage of development are expected to be approved during the forecast period. Of these molecules, one — vedolizumab — is indicated for the treatment of both UC and CD. The second molecule is a biosimilar of blockbuster drug Remicade (infliximab) and is expected to be launched following Remicade’s patent expiry.”
Additionally, almost 51% of the overall GI pipeline is in Phase II and Phase III development, of which 19 molecules are indicated for the treatment of IBS, 48 for UC and 41 for CD.
“The major factors currently stabilizing the market include the increasing prevalence of GI diseases, growing awareness of the importance of detecting these diseases early and the availability of effective diagnostics,” the analyst concludes.
*Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
